A prospective study of thalidomide in the treatment of ß-thalassemia in children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034998

Enrollment

Unknown

Registered

2020-07-27

Start date

2020-08-30

Completion date

Unknown

Last updated

2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ß-thalassemia

Interventions

Intervention group :Oral thalidomide

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 5-18 years; 2. Patients with intermediate or severe ß - thalassemia; 3. The family members of the children signed the informed consent; 4. Patients who did not participate in other clinical research projects in the first three months; 5. Patients who did not take other drugs interfering with the therapeutic effect.

Exclusion criteria

Exclusion criteria: 1. Patients with liver, kidney and heart dysfunction; 2. Patients with megaloblastic anemia and other anemia diseases; 3. Patients with other malignant tumor diseases or rheumatic immune diseases.

Design outcomes

Primary

Measure	Time frame
Hemoglobin;	—

Secondary

Measure	Time frame
Transfusion;Fetal hemoglobin;	—

Countries

China

Contacts

Public ContactJianpei Fang

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

jpfang2005@163.com+86 20-81332213

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026